[Butylon in inflammatory disorders of the adnexa].
D000632:Aminopyrine / Q000627:therapeutic use*; D002110:Caffeine; D004338:Drug Combinations; D005260:Female; D006801:Humans; D009525:Niacin / Q000627:therapeutic use*; D009539:Nicotinic Acids; D000292:Pelvic Inflammatory Disease / Q000628:therapy*; D010628:Phenetidine / Q000031:analogs & derivatives; D011343:Procaine / Q000627:therapeutic use*; D012457:Salicylamides; D012980:Sodium Salicylate / Q000627:therapeutic use*; D013831:Thiamine / Q000031:analogs & derivatives
D004338:Drug Combinations; D009539:Nicotinic Acids; D012457:Salicylamides; C023636:bucetin, caffeine, dibenzoylthiamine, ethenzamide drug combination; D000632:Aminopyrine; D010628:Phenetidine; D009525:Niacin; D002110:Caffeine; D011343:Procaine; D012980:Sodium Salicylate; D013831:Thiamine
ADNEXITIS/therapy; AMINOPYRINE/therapeutic use; NICOTINIC ACID/therapeutic use; PROCAINE/therapeutic use; SODIUM SALICYLATE/therapeutic use
Butylon bei entzündlichen Erkrankungen der Adnexe.